{
    "title": "Swiss pharma Helsinn, MEI scrap blood cancer therapy trial",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8483253/Swiss-pharma-Helsinn-MEI-abandon-late-stage-trial-blood-cancer-therapy.html",
    "date": "2020-07-02",
    "keywords": [
        "mei",
        "pharma",
        "helsinn",
        "bone",
        "marrow",
        "cancer",
        "aml",
        "pracinostat",
        "study",
        "combination",
        "therapy",
        "blood",
        "decision",
        "group",
        "analyst",
        "company",
        "inc",
        "thursday",
        "latestage",
        "type",
        "committee",
        "studys",
        "goal",
        "survival",
        "myeloid",
        "leukemia",
        "control",
        "azacitidine",
        "chemotherapy",
        "lack",
        "effectiveness",
        "safety",
        "laidlaw",
        "yale",
        "jen",
        "move",
        "pharmas",
        "value",
        "proposition",
        "drug",
        "development",
        "midstage",
        "asset",
        "me401",
        "lymphoma",
        "mei401",
        "thesis",
        "suntrust",
        "robinson",
        "robyn",
        "karnauskas",
        "addition",
        "bloodforming",
        "license",
        "market",
        "mds",
        "condition",
        "number",
        "immature",
        "replacement",
        "manojna",
        "maddipatla",
        "bengaluru",
        "editing",
        "shinjini",
        "ganguli",
        "maju",
        "samuel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}